Aeterna Zentaris, Inc. - AEZS STOCK NEWS

Aeterna Zentaris Inc. announced positive findings from its pediatric study of macimorelin for evaluating childhood-onset growth hormone deficiency (CGHD). The pharmacokinetics (PK) and pharmacodynamics (PD) profiles were comparable to adult data, supporting a 1.0 mg/kg dose for future studies. The Phase 3 trial, Study P02, is set to begin in Q1 2021. The study showed excellent safety and tolerability with no serious adverse events linked to macimorelin. This research aims to address significant unmet needs in CGHD treatment, enhancing the company's market position.

Aeterna Zentaris reported significant advancements in its clinical program for macimorelin, a diagnostic for growth hormone deficiencies. Positive results from Study P01 confirmed its dosing regimen for childhood-onset growth hormone deficiency. The company plans to initiate Study P02 in Q1 2021 and is in discussions to secure a commercialization partner in Europe. Financially, Aeterna raised $19 million in recent offerings, maintaining an operational runway through 2023. However, the company reported a net loss of $3.5 million for the second quarter of 2020, with total revenue decreasing to $0.07 million.

Aeterna Zentaris Inc. (NASDAQ: AEZS) has closed a registered direct offering, securing approximately $7 million through the sale of 12,427,876 common shares at $0.56325 each to institutional investors. Alongside, 9,320,907 unregistered warrants were issued at an exercise price of $0.47. Funds will primarily support a pediatric clinical trial for Macrilen™ (macimorelin) and pipeline development. The offering was facilitated by H.C. Wainwright & Co. and adheres to SEC regulations.

Aeterna Zentaris (NASDAQ: AEZS) announced a securities purchase agreement providing for the sale of approximately 12.4 million common shares at $0.56325 each, yielding gross proceeds of approximately $7.0 million. The offering includes unregistered warrants for 9.3 million shares, exercisable at $0.47 for 5.5 years. Proceeds will support a pediatric clinical trial for Macrilen (macimorelin), explore further therapeutic uses, and enhance pipeline development. The offering is anticipated to close around August 5, 2020, subject to customary conditions.

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced the filing of two patent applications on July 22, 2020, for macimorelin, a ghrelin agonist aimed at diagnosing growth hormone deficiencies in pediatric patients. The applications are based on positive outcomes from the AEZS-130-P01 study and are expected to bolster Aeterna's case for regulatory approval pending results from a subsequent pediatric study. Macimorelin is already FDA-approved for adult growth hormone deficiency and has shown the potential for expansion into pediatric uses.

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced the selection of its pediatric study abstract on macimorelin for presentation at the 22nd European Congress of Endocrinology (e-ECE 2020) set for September 5-9, 2020. The abstract, titled Pharmacokinetics and pharmacodynamics of macimorelin acetate in pediatric patients with suspected growth hormone deficiency, will be showcased as an ePoster with audio commentary. This study aims to address the unmet need in diagnosing child-onset growth hormone deficiency (CGHD), leveraging the company's successful existing product for adult diagnoses.

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced it received a notice from Nasdaq on July 27, 2020, indicating non-compliance with Listing Rule 5550(a)(2) due to a closing bid price under $1.00 for 30 consecutive business days. The company has a 180-day grace period until January 25, 2021, to regain compliance. Additionally, Aeterna raised approximately $10.5 million from a public offering, enhancing its stockholders' equity to at least $2.5 million, meeting minimum requirements for continued listing. Nasdaq's notice does not impact its listing on the Toronto Stock Exchange.

Aeterna Zentaris announced a public offering of 26,666,666 units priced at $0.45 each, aiming for gross proceeds of $12 million. Each unit includes one common share and one warrant exercisable at $0.45 for five years. The offering is expected to close on July 7, 2020.

The funds will primarily support a pediatric clinical trial for Macrilen™ (macimorelin) and further therapeutic research. The securities are being offered under an effective registration statement with the SEC.

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced an exclusive distribution agreement with Megapharm Ltd. for macimorelin in Israel and the Palestinian Authority. Megapharm will handle market registration, while Aeterna will manage manufacturing and regulatory support. The regulatory process for macimorelin is expected to conclude in the second half of 2021. This milestone aligns with Aeterna's goal to broaden its international distribution of macimorelin, a key product for diagnosing growth hormone deficiencies, having prior FDA and European approvals.